Premium
The Effects of Serum from Patients with Acute Liver Failure on the Growth and Metabolism of Hep G2 Cells
Author(s) -
Qingde Shi,
J.D.S. Gaylor,
Roderick Cousins,
John Plevris,
Peter Hayes,
M.H. Grant
Publication year - 1998
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.1998.06211.x
Subject(s) - bioartificial liver device , fulminant hepatic failure , liver failure , homeostasis , fulminant , medicine , cell culture , chemistry , endocrinology , biology , liver transplantation , hepatocyte , biochemistry , transplantation , genetics , in vitro
In many bioartificial liver systems currently being designed and evaluated for use in fulminant hepatic failure, direct contact is required between the patient's blood and the liver cells in the device. The efficacy of such devices will be influenced by the interaction of fulminant hepatic failure (FHF) patient serum with the cells. We have found that FHF serum inhibits the growth rate and the synthesis of DNA, RNA, and protein; disturbs glutathione homeostasis; and induces morphological changes in cultured human Hep G2 cells. These interactions should influence the design of bioartificial liver devices based on proliferating cell lines and indicate the requirement to pretreat FHF patient plasma to reduce the toxin load.